TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

VarmX and Rentschler Biopharma partner to advance novel coagulation therapy toward Phase 3 and commercialization

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Na
VarmX and Rentschler Biopharma partner to advance novel coagulation therapy toward Phase 3 and commercialization

VarmX and Rentschler Biopharma expanded their collaboration to manufacture VMX-C001, a novel coagulation therapy, for Phase 3 development and commercialization. The drug, which restores blood coagulation in patients on FXa DOACs requiring urgent surgery, has received FDA Fast Track Designation and PMDA Phase 1 waiver. Manufacturing will transition from Laupheim, Germany to Milford, MA, with Phase 3 trials expected to begin in early 2026.

Insights
CSLLY   positive

CSL's strategic collaboration and option agreement with VarmX (signed September 2025) provides exposure to a novel coagulation therapy with strong regulatory momentum and significant commercial potential in a large patient population requiring emergency surgery.